NUVB earnings analysis
What we found in NUVB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Nuvation Bio reported Q1 2026 results with significant revenue growth, reflecting a strong commercial launch of its product IBTROZI. Total revenue surged to $83.2 million from just $3.1 million in Q1 2025, driven primarily by product sales. However, diluted EPS decreased to $0.01 from $0.16 year-over-year, indicating ongoing financial challenges amid rising operating costs.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Surged by 2,596% YoY
- Nuvation reported $83.2 million in total revenue, up from just $3.1 million in Q1 2025.
- Commercial Launch of IBTROZI
- Product revenue from IBTROZI was approximately $18.5 million in Q1 2026 following its FDA approval.
- Collaboration Revenue Increased
- Collaboration and license agreements revenue rose by $61.6 million, mainly from an upfront payment under the Eisai agreement.
- Operating Cash Flow Positive
- Generated cash provided by operating activities of $5.1 million in Q1 2026.
- Strong Cash Position
- Ended Q1 2026 with $533.7 million in cash and marketable securities.
- Deficit Management Strategy in Place
- Management noted ongoing challenges but emphasized the strategy to maintain operations through potential funding.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Wider Losses Despite Revenue Growth
- Net loss increased to $40 million for Q1 2026, reflecting higher research and development expenses and operational costs.
- Dependence on IBTROZI Performance
- Future revenue heavily relies on successful commercialization of IBTROZI and market acceptance.
- Regulatory Compliance Risks
- Navigating complex Chinese data privacy laws poses a potential risk affecting international operations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.01
- Segment
- Product revenue: $18.5 million
- Segment
- Collaboration revenue: $64.7 million
What they said about what is next.
Outlook for the second quarter anticipated to be discussed during the upcoming earnings call.
The filing reads better than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NUVB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever